Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xinfeng Yang

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Annals of Translational Medicine|May 16, 2022
Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancerGuanghui Gao, Jun Zhao, Shengxiang Ren, et al.
BMC Medicine|March 4, 2022
Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trialXiaojian Qin, Dongmei Ji, Weijie Gu, et al.
Innovation (Cambridge (Mass.))|January 28, 2025
Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket studyLuoyan Ai, Qian Li, Shilong Zhang, et al.
Journal for Immunotherapy of Cancer|February 22, 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trialShengxiang Ren, Xicheng Wang, Bao-Hui Han, et al.
Med (New York, N.Y.)|October 17, 2024
Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trialXiaojie Bian, Weijie Gu, Xuepei Zhang, et al.
Translational Lung Cancer Research|July 14, 2022
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring <i>EGFR</i> or <i>ALK</i> genetic aberrationGuanghui Gao, Jian Ni, Yina Wang, et al.
Nature Communications|July 2, 2025
Mast cells boost anti-tumor potency of MAIT cells via inflammasome-dependent secretion of IL-18Fanfan Fan, Jun Wang, Kun Liu, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2024
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket studyShengxiang Ren, Anwen Xiong, Jia Yu, et al.
Signal Transduction and Targeted Therapy|December 17, 2024
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 studyHongkai Wang, Shusuan Jiang, Hong Luo, et al.
The Lancet. Oncology|September 8, 2022
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trialWeijie Gu, Weiqing Han, Hong Luo, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Annals of Translational Medicine|May 16, 2022
Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancerGuanghui Gao, Jun Zhao, Shengxiang Ren, et al.
BMC Medicine|March 4, 2022
Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trialXiaojian Qin, Dongmei Ji, Weijie Gu, et al.
Innovation (Cambridge (Mass.))|January 28, 2025
Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket studyLuoyan Ai, Qian Li, Shilong Zhang, et al.
Journal for Immunotherapy of Cancer|February 22, 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trialShengxiang Ren, Xicheng Wang, Bao-Hui Han, et al.
Med (New York, N.Y.)|October 17, 2024
Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trialXiaojie Bian, Weijie Gu, Xuepei Zhang, et al.
Translational Lung Cancer Research|July 14, 2022
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring <i>EGFR</i> or <i>ALK</i> genetic aberrationGuanghui Gao, Jian Ni, Yina Wang, et al.
Nature Communications|July 2, 2025
Mast cells boost anti-tumor potency of MAIT cells via inflammasome-dependent secretion of IL-18Fanfan Fan, Jun Wang, Kun Liu, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2024
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket studyShengxiang Ren, Anwen Xiong, Jia Yu, et al.
Signal Transduction and Targeted Therapy|December 17, 2024
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 studyHongkai Wang, Shusuan Jiang, Hong Luo, et al.
The Lancet. Oncology|September 8, 2022
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trialWeijie Gu, Weiqing Han, Hong Luo, et al.
Pageof 4